Vanguard National Trust
EW icon

Vanguard National Trust’s Edwards Lifesciences EW Stock Holding History

Vanguard National Trust’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Hold
1,521
– – 0.01% 317
2026
Q1 		$122K Buy
+1,521
New +$125K 0.01% 302

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Vanguard National Trust's EW Position: Q2 2026 in Review

Vanguard National Trust held its Edwards Lifesciences (EW) position steady in Q2 2026 at 1,521 shares worth $138K. The position accounts for 0.01% of the portfolio, ranked #317.

Vanguard National Trust first reported a position in EW in Q1 2026 and has held it in 2 quarters since. 1,316 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Vanguard National Trust held 1,521 shares of Edwards Lifesciences worth $138K as of Q2 2026.
  • Vanguard National Trust left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up 0.01% of Vanguard National Trust's portfolio in Q2 2026, its #317 holding.
  • Vanguard National Trust first reported a position in Edwards Lifesciences in Q1 2026 and has held it in 2 quarters since.
  • 1,316 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.